arrow
返回

Introduction and background

delete2016-11-01
delete103
delete
OA
AI
A
Andrew Fisher *
A
Anders Andreasson
A
Alexandros Chrysos
J
Joanne Lally
C
Chrysovalanto Mamasoula
C
Catherine Exley
J
Jennifer Wilkinson
J
Jessica Qian
G
Gillian Watson
O
Oli Lewington
T
Thomas Chadwick
E
Elaine McColl
M
Mark S. Pearce
K
Kay Mann
N
Nicola McMeekin
L
Luke Vale
S
Steven Tsui
N
Nizar Yonan
A
André Simon
N
Nándor Marczin
J
Jorge Mascaro
J
John H. Dark
DOI:10.3310/hta20850delete
delete原文链接
delete分享
delete收藏
摘要

摘要

En 中文
Respiratory diseases account for one in five deaths in the UK.(1) Lung transplantation is the only realistic therapeutic option for selected patients with end-stage chronic lung disease and provides dramatic improvements in both survival and quality of life. In younger patients with life-threatening cystic fibrosis (CF) lung disease, median survival after lung transplant now exceeds 10 years. However, 20-30% of patients waiting for lung transplantation will die before a donor organ becomes available. Although a shortage of multiorgan donors contributes, the main problem is that in multiorgan donors lungs are very susceptible to dysfunction, and about 80% of potential donor lungs in the UK are deemed unusable for clinical lung transplantation. It has previously been suggested that, in addition to promoting more organ donation, better use of existing organ donors is an important way to increase the numbers of lung transplants performed, 2 and many centres worldwide have increased donor lung use by accepting more 'marginal' or 'extended criteria' donors. This, however, is not without risks to early post-transplantation outcomes. 3 The major early cause of death after lung transplantation is primary graft dysfunction (PGD), a severe lung injury akin to acute respiratory distress syndrome. Evidence that PGD has a major impact on survival comes from experience in several centres worldwide, 4 and from the International Society for Heart and Lung Transplantation (ISHLT); the reported incidences of PGD are up to 25%, and PGD is associated with 30-day mortality of 50%, compared with < 10% among those without PGD.(5) There is, therefore, an urgent clinical need to safely increase the utilisation of donor lungs from the existing donor pool without negatively impacting on early survival after lung transplant.
Keyword:
VIVO LUNG PERFUSION
PRIMARY GRAFT DYSFUNCTION
REJECTED DONOR LUNGS
ISHLT WORKING GROUP
INTERNATIONAL-SOCIETY
INTERLEUKIN-10 GENE
INFORMED-CONSENT
BRAIN-DEATH
RAT LUNG
TRANSPLANTATION

期刊

H
Health Technology Assessment
IF:
4
论文数:
1.8K
被引数:
6.2K

机构

W
wythenshawe hospital nhs foundation trust
学者数:
5
论文数: 27
被引数: 6
H
Harefield Hospital
学者数:
3
论文数: 8
被引数: 0
N
newcastle university - uk
学者数:
0
论文数: 525
被引数: 31
U
University of Birmingham
学者数:
1.6K
论文数: 731
被引数: 1
N
Newcastle upon Tyne Hospitals NHS Foundation Trust
学者数:
83
论文数: 32
被引数: 2
Papworth Hospital 封面图
Papworth Hospital
学者数:
2.0K
论文数: 1.5K
被引数: 2.1K
学者 查看更多机构
引用论文

引用论文

err分享
err收藏
err分享
err收藏
Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans
err2006-03-01
err111
PREAI
errKaneda, H; Waddell, TK; de Perrot, M; Bai, XH; Gutierrez, C; Arenovich, T; Chaparro, C; Liu, M; Keshavjee, S
err分享
err收藏
err分享
err收藏
err
IF0
err
err0
PREAI
err
err分享
err收藏
Exhaled Breath Condensate in Mechanically Ventilated Brain-injured Patients with No Lung Injury or Sepsis
err2011-05-01
err17
errOAAI
errKorovesi, Ioanna; Papadomichelakis, Evangelos; Orfanos, Stylianos E.; Giamarellos-Bourboulis, Evangellos J.; Livaditi, Olga; Pelekanou, Aimilia; Sotiropoulou, Christina; Koutsoukou, Antonia; Dimopoulou, Ioanna; Ekonomidou, Foteini; Psevdi, Ekaterini; Armaganidis, Apostolos; Roussos, Charis; Marczin, Nandor; Kotanidou, Anastasia
err分享
err收藏
学者 查看更多内容